Nesiritide can ease the strain of acute heart failure by widening blood vessels, but that effect may lower blood pressure too far. Close monitoring helps clinicians spot hypotension early and protect organ perfusion, while lung sounds, breathing, and urine output add useful context about the patient’s condition.

Multiple Choice

What is the priority assessment for a patient receiving IV nesiritide (Natrecor) to treat heart failure?

Nesiritide is a vasodilator used in acute heart failure, so the most important thing to monitor is blood pressure. Its effect is to lower systemic vascular resistance and blood pressure, which can lead to hypotension and reduced organ perfusion. Therefore, checking the patient's BP closely during the IV infusion is essential to detect hypotension early and adjust or stop the infusion if needed. While urine output, lung sounds, and respiratory rate provide useful information about fluid status and pulmonary congestion, they do not carry the same immediate safety risk as a potential drop in blood pressure with this therapy.

In acute heart failure, a medication that eases the heart’s workload can also cause a sudden drop in blood pressure. That’s why blood pressure is the priority assessment when a patient receives IV nesiritide (Natrecor). The drug can help relieve symptoms, but its blood-vessel effects may reduce circulation to vital organs if the pressure falls too far. Close monitoring helps clinicians spot that risk early and respond.

Heart failure care involves several moving parts: breathing, fluid levels, kidney function, circulation, and more. Lung sounds, respiratory rate, and urine output all offer useful clues about a patient’s condition. But when nesiritide is being infused, blood pressure has a direct link to one of the drug’s most important—and potentially dangerous—effects.

What nesiritide does

Nesiritide is a synthetic form of B-type natriuretic peptide, a hormone the body releases in response to strain on the heart. It acts on blood vessels and the kidneys. By increasing a signaling molecule called cyclic GMP, nesiritide relaxes blood vessels and lowers vascular resistance. This can reduce the amount of force the heart must work against.

The drug also relaxes veins, which can lower the volume of blood returning to the heart. In simple terms, the heart may face less pressure as it pumps and less filling volume to manage. These effects can ease some symptoms of acute, decompensated heart failure, including shortness of breath.

Yet the same action that may reduce the heart’s workload can lower systemic blood pressure. A medication’s benefit and risk often share a doorway: the drug changes the body in a helpful way, but that change can go too far. With nesiritide, a sharp or sustained fall in pressure may leave organs with less blood flow.

Why blood pressure comes first

Blood pressure reflects the force that moves blood through the body. If it drops too low, the brain, kidneys, and other organs may not receive enough blood to function well. A patient may become dizzy, faint, confused, weak, or unusually tired. In severe cases, poor organ perfusion can become a medical emergency.

Nesiritide can cause hypotension, sometimes soon after the infusion begins or after the dose changes. Monitoring blood pressure closely gives the care team a timely warning. They can assess the patient, review the infusion, and take steps such as adjusting or stopping it, based on the treatment plan and the patient’s condition.

That does not mean other assessments can wait. It means blood pressure deserves particular attention because it is closely tied to the medication’s immediate safety profile. A complete assessment still includes the whole patient, not just one number on a monitor.

The other clues matter, too

Lung sounds can reveal fluid in the lungs. Crackles, for example, may occur when fluid collects in the small airways and air sacs. Listening to the lungs helps clinicians assess pulmonary congestion and whether breathing symptoms are changing.

Respiratory rate also matters. A rising rate, labored breathing, or a new need for more oxygen can signal worsening respiratory distress. These findings help show whether the patient’s heart failure symptoms are improving or getting worse.

Urine output offers another important clue. The kidneys help regulate fluid balance, and low output may point to reduced kidney perfusion, worsening heart failure, or another problem. Tracking output can help clinicians understand how the patient is responding to treatment.

Each measure answers a different question. Lung sounds and breathing show what is happening in the lungs; urine output offers insight into kidney function and fluid balance. Blood pressure, meanwhile, helps identify whether nesiritide is lowering circulation pressure to an unsafe level. That direct connection makes it the priority while the drug is infusing.

What clinicians watch during an infusion

Before starting nesiritide, clinicians consider the patient’s blood pressure and overall hemodynamic condition. A low starting pressure can raise concern because the medication may lower it further. They also review the patient’s other medicines and medical history, since these can affect blood pressure and treatment risk.

During the infusion, blood pressure is checked at intervals set by the care plan and the medication’s prescribing guidance. The team also watches for symptoms of hypotension and changes in mental status, skin temperature, pulse, breathing, and urine output. A patient’s report matters, too. New dizziness or faintness should not be brushed aside as a minor complaint.

If pressure falls, the response depends on how low it is, how the patient feels, and what else is happening. Clinicians may adjust the infusion or stop it, while assessing the patient and considering other causes of the change. They may also review fluid status and other medications. The aim is not simply to raise a number; it is to protect blood flow to the organs while treating heart failure.

A useful distinction: monitoring is not a single number

Blood pressure is the priority assessment, but one reading never tells the full story. A reading should be interpreted alongside the patient’s usual pressure, symptoms, pulse, and broader clinical picture. A value that is normal for one person may be a major change for another.

Trend matters. If the pressure is steadily falling, that pattern can be concerning even before the patient reports symptoms. On the other hand, a single unusual reading may need to be checked again, especially if the patient’s position or the measurement technique could have affected it. Good clinical monitoring combines accurate measurements with observation and sound judgment.

This is one reason heart failure care can feel like keeping several dials in view at once. Blood pressure may be the most urgent dial during a nesiritide infusion, but breathing, kidney function, fluid balance, and mental status still shape the overall picture.

The balance between relief and risk

Acute heart failure can make breathing difficult and place extra strain on the heart. Medicines that relax blood vessels may help reduce that strain, but they must be used with attention to their effects on circulation. Nesiritide is not simply a “fluid medicine” or a general treatment for every person with heart failure; clinicians weigh its potential benefits and risks for each patient.

Its blood-pressure-lowering effect explains the monitoring priority. If pressure drops too far, the body may not move enough blood to essential organs. Watching blood pressure closely helps the care team catch that problem and act, while ongoing checks of lung sounds, respiratory rate, and urine output show how the heart failure itself is changing.

In short, nesiritide’s action offers the clearest guide to what needs watching first: blood pressure. The other assessments remain valuable, but close blood-pressure monitoring is central to using the infusion safely.